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ABSTRACT
Multiple myeloma (MM) is closely associated with bone destruction. Once 
migrated to the bone marrow, MM cells unbalance bone formation and resorption via 
the recruitment and maturation of osteoclast precursors.
The Notch pathway plays a key role in different types of cancer and drives 
several biological processes relevant in MM, including cell localization within the 
bone marrow, proliferation, survival and pharmacological resistance. 
Here we present evidences that MM can efficiently drive osteoclastogenesis by 
contemporaneously activating Notch signaling on tumor cells and osteoclasts through 
the aberrant expression of Notch ligands belonging to the Jagged family. Active Notch 
signaling in MM cells induces the secretion of the key osteoclastogenic factor, RANKL, 
which can be boosted in the presence of stromal cells. In turn, MM cells-derived 
RANKL causes the upregulation of its receptor, RANK, and Notch2 in pre-osteoclasts. 
Notch2 stimulates osteoclast differentiation by promoting autocrine RANKL signaling. 
Finally, MM cells through Jagged ligands expression can also activate Notch signaling 
in pre-osteoclast by direct contact.
Such synergism between tumor cells and pre-osteoclasts in MM-induced 
osteoclastogenesis can be disrupted by silencing tumor-derived Jagged1 and 2. These 
results make the Jagged ligands new promising therapeutic targets in MM to contrast 
bone disease and the associated co-morbidities.
INTRODUCTION
Multiple myeloma (MM) is a malignant plasma 
cell (PC) disorder accounting for approximately 10% of 
all hematological cancers. Although recent advances in 
treatment, myeloma remains an incurable disease [1].
MM is associated with osteoclast-mediated  bone 
destruction, and consequent osteoporosis, hypercalcaemia, 
bone pain and fractures. Altogether, bony lesions are 
observed in up to 80% of patients [1, 2]. 
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Circulating malignant PCs are recruited into the 
bone marrow (BM) by a chemotactic gradient involving 
the SDF-1/CXCR4 axis [3, 4]. BM-infiltrating MM cells 
induce BM stromal cells to increase the production of 
osteogenic factors such as the receptor activator of NF-κB 
ligand (RANKL) and may directly contribute to increase 
the level of RANKL [5, 6] and other pro-osteoclastogenic 
chemokines [6-8]. These events alter the ratio between 
RANKL and its decoy receptor, osteoprotegerin, thus 
increasing osteoclast (OCL) formation [9]. 
OCLs are involved in supporting MM cell long-
term survival, proliferation and drug resistance [10], 
and promote TGF-β release from the bone matrix, which 
plays a role in antagonizing patient’s anti-tumor immune 
responses [11]. They also cooperate with MM cells to 
stimulate new vessels formation, which in turn  are able to 
induce osteoclastogenesis, promoting a vicious circle that 
leads to MM progression and bone lesions [12]. 
The Notch family includes four transmembrane 
receptors (Notch1-4), which are activated by ligands 
belonging to two families, Jagged (Jagged1, 2) and 
Delta-like (Dll1,3, 4). Receptor engagement activates the 
ADAM/TACE and the γ-secretase complex, triggering two 
proteolytic cleavages and the release of the intracellular 
portion of Notch (ICN).  ICN translocates to the nucleus 
and activates the CSL (CBF1, Suppressor of hairless, Lag-
1) transcription factor [3].
The Notch pathway plays a critical role in cell-
fate decision, tissue patterning and morphogenesis and 
is dysregulated in a variety of malignancies [13, 14] 
including those affecting T- [15-17] and B-cells [18-20]. 
Importantly, Notch receptors are expressed by MM cells, 
BM stromal cells (BMSCs), and OCLs. MM cells activate 
the Notch pathway due to the over-expression of Jagged1 
and Jagged2 ligands [21-23]. Jagged1 expression in 
malignant PCs arises upon progression from monoclonal 
gammopathy of undetermined significance (MGUS) 
to MM [23]. Jagged2 dysregulation [21, 24, 25] is an 
early event preceding MGUS, positively correlated with 
stage [24] and can be driven by epigenetic events [21] or 
overexpression of the ubiquitin-ligase Skeletrophin [25].
Functional evidences from this and other groups 
indicate that the active Notch signaling is involved in MM 
pathogenesis [3] and that its inhibition induces MM cell 
apoptosis, reduces drug resistance, and MM cell migration 
to the BM [4, 26]. The Notch pathway plays also a key 
role in bone tissue remodeling and skeletal development 
together with the NF-κB pathway [27-29]. 
Here, we provide experimental evidences that the 
Notch pathway drives MM-associated OCL development 
and bone destruction, which can be prevented by the 
inhibition of the dysregulated Jagged ligands on MM cells.
RESULTS
Notch signaling is required for myeloma-mediated 
osteoclastogenesis
The Notch pathway is essential in skeletal 
development and remodeling [27], since it drives OCL 
differentiation as reported by Fukushima et al. [28]  and 
confirmed by our results which further indicate that Notch 
Figure 1: MM cells induce osteoclast 
differentiation in a Notch-dependent 
manner. Co-culture system of Raw264.7 cells 
and U266 cells results in osteoclast differentiation 
which can be prevented by DAPT. (A) TRAP 
staining and enumeration of TRAP+/multinucleated 
cells in 7 days-single culture or co-cultures with 
or without DAPT. (B) Pit formation in the same 
cultures as (A) maintained for 10 days. (C) The 
relative gene expression of TRAP and RANK 
(normalized to GAPDH) in Raw264.7 + U266 cells 
± DAPT was compared to Raw264.7 (DMSO) by 
the 2−ΔΔCt formula. Graph shows the mean values 
± SD. Two-tailed t-test confirmed statistically 
significant variations in the expression levels of 
RANK and TRAP when comparing co-cultures to 
single cultures in the presence of  DMSO or DAPT; 
**= p <0.01, ***= p <0.001). 
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activity positively regulates RANK expression during 
osteoclastogenesis (Fig. S1). 
These findings and the evidence that Notch plays 
a crucial role in MM cell biology [3] prompted us to 
investigate the contribution of Notch signaling in MM-
induced osteoclastogenesis by analyzing: 1) MM cell 
osteoclastogenic property and 2) OCL differentiation.
To investigate if the Notch pathway contributes to 
the process by which MM cells induce osteoclastogenesis, 
the U266 human MM cell line was co-cultured for 7 
days with Raw264.7 cells with or without 50μM DAPT. 
U266 cells readily induced the formation of TRAP+/
multinucleated Raw264.7 cells, which was significantly 
inhibited by DAPT (~70%). This finding indicated that the 
pro-osteoclastogenic ability of MM cells was dependent 
on active Notch signaling (Fig. 1A). Furthermore, Notch 
inhibition also impaired the osteolytic activity of OCLs 
generated in a 10 days Raw264.7/U266 co-culture assay 
(Fig. 1B). The need of an active Notch signaling in MM-
induced osteoclastogenesis was further confirmed by the 
decrease in TRAP and RANK gene expression in Raw264.7 
cells after DAPT treatment (Fig. 1C). 
MM cells induce OCLs formation by secreting 
RANKL in a Notch-dependent way
We wondered if the ability of MM cell to induce 
Notch-dependent osteoclastogenesis was reliant upon 
the secretion of soluble factors. To test this hypothesis, 
we evaluated the osteoclastogenic property of U266 
conditioned medium (CM). The contribution of U266-
derived soluble factors was confirmed by the evidence 
that the addition of CM (20% V/V) to Raw264.7 cells 
for 7 days induced productive OCL differentiation. As 
expected, DAPT dramatically reduced CM-dependent 
osteoclastogenesis (Fig. 2A, CM U266 and CM U266 + 
DAPT), but more importantly the addition of CM from 
Figure 2: MM cells induce OCLs formation by a Notch-dependent release of RANKL. To assess if MM cell osteoclastogenic 
property was dependent on Notch-driven secretion of soluble factors we evaluated the ability of U266-CM to induce OCL formation. 
(A) TRAP staining and enumeration of multinucleated Raw264.7 cells exposed to CM from U266 and additionally treated or not with 
DAPT, or exposed to CM obtained from DAPT-treated U266. Mean values ± SD are shown. Statistical analysis by ANOVA and Tukey 
test: **= p<0.01, ***= p <0.001. We also evaluated the ability of DAPT to inhibit RANKL expression in U266 cell line. (B) ELISA assay 
on RANKL protein released by U266 cell line in the CM after 48 and 96h DAPT treatment. SD were calculated from 3 independent 
experiments. Statistical analysis was performed using Two-tailed t-test: **= p<0.01. (C) qPCR measure of relative RANKL gene expression 
variation in DAPT-treated U266 cells compared to untreated cells, calculated by the 2−ΔΔCt formula (as in Fig.1C); HES6 gene expression 
variation confirmed DAPT treatment effectiveness. (D) U266 osteoclastogenic properties relies on the secreted RANKL: treatment with 
anti-RANKL antibody dramatically depletes OCL formation (TRAP+/multinucleated cells) in Raw264.7 cells cultured with U266 cells or 
U266-CM respect to the relative untreated controls (=100%). p<0.05 by ANOVA and Tukey post test for Raw264.7/U266/anti-RANKL vs 
Raw264.7/U266 and for Raw264.7/U266-CM/anti-RANKL vs Raw264.7/U266-CM . 
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DAPT-treated U266 cells (Fig. 2A) was unable to induce 
OCL differentiation suggesting that the activation of 
Notch signaling was necessary for MM cells to produce 
osteoclastogenic soluble mediators. 
Since Raw264.7 cell differentiation requires 
only RANKL stimulation, and MM cell ability to yield 
osteoclastogenic soluble factors depended on Notch 
activity, we hypothesized that U266 cells produced 
RANKL in a Notch-controlled manner. Indeed, U266 
cells secreted 9.7 ng/ml and 14 ng/ml in 48h and 96h, 
respectively (Fig. 2B). DAPT treatment induced a 
significant decrease in RANKL transcript (Fig 2C) and 
secreted protein (Fig. 2B). DAPT effectiveness was 
confirmed by down-regulation of HES6 expression. We 
confirmed that U266 cells pro-osteoclastogenic potential 
mainly depended on soluble RANKL released by these 
cells, indeed neutralizing RANKL antibody added to the 
co-culture system or U266 CM, dramatically reduced OCL 
differentiation (Fig. 2D). 
MM cell-derived RANKL promotes OCLs 
differentiation via Notch2 but not Notch1 
Since RANKL secretion seemed to be crucial in 
determining the osteoclastogenic property of  MM cells, 
we focused on the outcome of RANKL stimulation on 
OCL progenitors. Basing on Duan and colleagues [30] 
RANKL stimulation resulted in Notch signaling activation 
in OCLs, therefore we wondered if U266 cells were able 
Figure 3: Notch2 is essential for OCL differentiation and drives RANKL secretion. (A) U266 cells and U266-CM induce 
Notch activation in Raw264.7 cells: change in Notch activity level was measured as relative HES5 gene expression variation in Raw264.7 
cells cultured with U266 cells, U266-CM or RANKL compared to single cultured untreated cells (=1), and calculated by the 2−ΔΔCt formula 
(as above). Mean values ± SD were shown. Two-tailed t-test confirmed statistically significant variation of Notch activity upon each 
treatment. (B) the relative gene expression of Notch1 and Notch2 (normalized to GAPDH) in Raw264.7 cells induced to differentiate in the 
presence of mRANKL or U266 cells compared to undifferentiated cells (2−ΔΔCt).  (C) TRAP staining and enumeration of multinucleated cells 
in Raw264.7 cells 72h after electroporation with plasmids expressing Notch1 or Notch2. The graph shows the mean value ± SD. Statistical 
analysis by ANOVA and Tukey post-test; **= p <0.01   (D) ELISA for RANKL secretion in CM from transfected Raw264.7 cells. Mean 
values ± SD are shown. Statistical analysis by ANOVA and Tukey post-test (***=p <0.001).  (E) Enumeration of TRAP+/multinucleated 
cells on Raw264.7 cells exposed to the CM from ICN1- or ICN2-transfected Raw264.7 cells, or the CM from ICN2-transfected cells 
with RANKL neutralizing antibody. Results were normalized to CM from mock cells (for ICN1- and ICN2-transfections) or mock cells 
+ RANKL neutralizing antibody (only for CM from ICN2-transfected cells). Standard deviations were calculated from 3 independent 
experiments and statistical significance (ICN1 vs ICN2; ICN2 vs ICN2+anti-RANKL) was verified by Two-tailed t-test (*=p <0.05).
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to trigger Notch signaling in Raw264.7 cells by releasing 
RANKL. At this purpose, Raw264.7 cells were cultured 
for 5 days with U266 cells, U266-CM (20% V/V) or 
mRANKL alone (50 ng/mL). In all conditions HES5 
transcript was up-regulated (Fig.3A), thus indicating 
that MM cells could trigger the osteoclastogenic Notch 
signaling in OCL precursors by releasing RANKL and did 
not necessarily need a direct interaction. 
We wondered if the observed changes in Notch 
signaling could be due to a variation in the expression 
of Notch isoforms relevant in MM. Our results showed 
that OCL differentiation induced by RANKL or MM cells 
was associated to an increase in Notch2 and a decrease 
in Notch1 level (Fig. 3B), suggesting a different role for 
the two Notch isoforms during osteoclastogenesis. To 
address this issue, we analyzed the effect of the two Notch 
isoforms by transiently transfecting Raw264.7 cells with 
plasmids carrying ICN1 and ICN2. Increased expression 
and activity of  Notch1 and 2 was confirmed by Western 
blot for their active forms (Fig.S2-panel A), and by RT-
PCR for the Notch transcriptional target gene HES5 (Fig.
S2-panel B). Figure 3C shows that ICN2, but not ICN1, 
induced Raw264.7 cell osteoclastogenesis and increased 
TRAP expression 3 days after electroporation (Fig.S2-
panel B). ICN2 stimulated the expression of  RANKL 
in Raw264.7 cells, as confirmed by PCR (Fig.S2-panel 
B) and ELISA (Fig.3D). Moreover, the CM from ICN2-
transfected Raw264.7 cells induced osteoclastogenesis 
when added to not-transfected Raw264.7 cells after 7 days 
(Fig.3E). To confirm that this effect was dependent on the 
increased RANKL production, a neutralizing anti-RANKL 
antibody was added to the CM from ICN2-transfected 
Raw264.7 cells. RANKL neutralization significantly 
inhibited the ability of CM to induce osteoclastogenesis 
(Fig.3E and Fig.S2-panel C). 
RANKL expression in CD138+ cells from MM 
patients is correlated with Notch pathway 
activation
To investigate if RANKL gene expression in MM 
cells could be associated with Notch pathway activation 
in MM patients, we evaluated RANKL and Notch target 
HES6 gene expression profiles from a proprietary data set 
(GEO accession number: GSE 39925) of highly purified 
PC samples from 55 newly-diagnosed MM patients 
[31] profiled on Affymetrix Gene 1.0 ST array. Analysis 
revealed a significant correlation between the Notch target, 
HES6, and RANKL expression levels (Fig. 4A; Pearson’s 
correlation coefficient=0.53439).
Furthermore, validation qRT-PCR on mRNA from 
17 MM patients’ CD138+ cells confirmed the correlation 
between HES6 and RANKL transcript levels (Fig. 4B, 
Pearson’s correlation coefficient=0,9087). Analogously, 
HES6 level was higher in the high RANKL-expressing 
U266 cells in comparison to the low RANKL-expressing 
MM OPM2 cell line (Fig. 4C). These findings are 
consistent with the evidence that RANKL expression by 
MM cells depends upon Notch activity. 
Notch signaling inhibition reduces the 
osteoclastogenic potential of primary human MM 
cells
To confirm the crucial role of Notch signaling in 
MM-associated bone disease ex vivo, we inhibited the 
Notch signaling during the differentiation of primary 
human monocytes induced by addition of osteoclastogenic 
factors or by co-culturing with primary human MM cells. 
Purified human CD14+ monocytes were cultured 
Figure 4: Notch pathway activation is correlated 
with RANKL expression levels in MM patients. (A) 
Correlation of RANKL and HES6 gene expression levels in 
purified PC samples from 55 MM patients profiled on Affymetrix 
Gene 1.0 ST array. Statistical analysis was performed with 
Pearson’s rank correlation test (p= 2.6e-05). (B) qRT-PCR of 
RANKL and HES6 genes on 17 MM patients. Gene expression 
is relative to GAPDH. Statistical analysis: Pearson’s correlation 
coefficient=0,9087; p<0,0001. (C) qRT-PCR for HES6 and 
RANKL on U266 and OPM2 cell lines. Data are presented as 
the relative expression in U266 vs OPM2 (=1), calculated by the 
2−ΔΔCt formula (see above). Mean values ± SD of 3 independent 
experiments are shown.
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with M-CSF and RANKL in the presence of 25 µM 
DAPT for 8 days. DAPT significantly reduced RANKL-
induced OCL differentiation (Fig. 5A) and suppressed 
the upregulation of the transcript levels of RANK and 
Cathepsin K at day 3 (Fig. 5B). At the same time, we 
performed co-cultures of human CD14+ monocytes with 
primary human CD138+ cells purified from myeloma 
patient BM aspirates. DAPT significantly inhibited the 
ability of myeloma cells to induce osteoclastogenesis 
(Fig. 5C), confirming the results in previously described 
Raw264.7/U266 co-cultures.
MM-derived Jagged ligands promote OCL 
differentiation by activating Notch signaling on 
MM cells and pre-OCLs
Notch pathway dysregulation in MM is mainly 
due to the alterations of two Notch ligands, Jagged1 
and Jagged2. To test their contribution in MM-induced 
osteoclastogenesis, Raw264.7 were cultured for 7 days 
Figure 5: Inhibition of Notch signaling inhibits RANKL- and myeloma cell-induced osteoclastogenesis. (A) Human 
CD14+ monocytes (n = 6) were stimulated with M-CSF or M-CSF plus RANKL in the absence (DMSO) or presence of DAPT (25µM). 
After 8 days the number of TRAP+ multinucleated cells (≥3 nuclei) was enumerated. Representative images are shown for each condition 
and a box & whisker plot, where the boxes represent the 25th to 75th percentiles, the lines within the boxes represent the median, and the 
lines outside the boxes represent the 5th and 95th percentiles, show the absolute number of TRAP+ multinucleated cells. **= p < 0.01 by a 
one-way ANOVA with Tukey’s multiple comparison post-test. (B) RNA was extracted at day 3 and q-RT-PCR was performed to evaluate 
the level of RANK and Cathepsin K expression. Gene expression was normalized to B2M and the fold-change was calculated by qRT-PCR 
as reported above. Significance was determined by a Wilcoxon matched-pairs signed rank test. (C) Human CD14+ pre-osteoclasts were 
stimulated with M-CSF or M-CSF plus co-cultured with primary myeloma cells in the absence (DMSO) or presence of DAPT (25µM). 
After 7 days the number of TRAP+ multinucleated cells (≥3 nuclei) was enumerated. Representative images and a box & whisker plot, 
where the boxes represent the 25th to 75th percentiles, the lines within the boxes represent the median, and the lines outside the boxes 
represent the 5th and 95th percentiles, show the absolute number of TRAP+ multinucleated cells per image (n = 8) for one experiment. 
***= p < 0.001 by a one-way ANOVA with Dunnett’s multiple comparison post-test. This was repeated in 4 independent experiments and 
the % inhibition over the experiments is shown in the bar graph. *= p<0.05 by Mann-Whitney test.
Oncotarget7www.impactjournals.com/oncotarget
with the CM from U266 transfected with Jagged1 and 
Jagged2 siRNAs (J1/J2) or the corresponding scrambled 
siRNAs (Scr). J1/J2 silencing did impair the ability of 
U266 CM to promote the generation of osteolytically 
active TRAP+/multinucleated cells (Fig. 6A and 6B), 
and compromised the upregulation of TRAP and RANK 
expression in Raw264.7 (Fig. 6C). The effectiveness of 
J1/J2 silencing in U266 cells and the consequent Notch 
pathway inhibition were verified by qRT-PCR shown 
in Fig. 6D; two housekeeping genes (18s and HPRT1) 
were used as control of siRNAs specificity. qRT-PCR 
analysis revealed that the expression level of RANKL was 
significantly reduced in J1/J2-silenced U266 cells after 
48h (Fig. 6D). This effect was associated with decreased 
expression of soluble RANKL in CM (Fig. 6E). These 
results further support the evidence that MM cells require 
Jagged-activated Notch to trigger OCL differentiation 
through the expression of RANKL. 
Finally, it is an accepted notion that not all primary 
MM cells and cell lines are able to secrete significant 
amounts of RANKL [32, 33], i.e. OPM2 cells express very 
low levels of RANKL (Fig.4C). To verify if the interaction 
with BMSCs could enhance the osteoclastogenic potential 
of low RANKL-expressing MM cells, we get advantage 
Figure 6: Jag1/2 silencing impairs MM cell osteoclastogenic ability. To verify if U266-derived Jagged ligands affect the release 
of soluble osteoclastogenic factors, Raw264.7 cells were cultured in the presence of CM from J1/J2- or Scr-transfected U266 cell line. 
The osteoclastogenic ability  of J1/J2-silenced U266  CM  was abated as shown by:  (A)  TRAP staining and enumeration of TRAP+/
multinucleated Raw264.7 cells and (B) Pit formation assay. Statistical analysis was performed using the ANOVA and Tukey test: ***= 
p <0.001; (C) RANK and TRAP genes upregulation is reduced in Raw264.7 cells cultured in the presence of J1/J2-silenced U266 CM 
compared to Scr-U266 CM. Data are presented as mean values ± SD of relative gene expression calculated by the 2−ΔΔCt formula (see 
above). Two-tailed t-test confirmed statistically significant variations in the expression levels of RANK and TRAP induced by J1/J2- or Scr- 
transfected U266; *= p <0.05, **= p <0.01. Jagged ligands inhibition resulted in a reduced secretion of RANKL by MM cells.  U266 cells 
were transfected with J1/J2 specific siRNAs or with the Scr control: (D) qRT-PCR of RANKL gene expression 48h post transfection in J1/
J2-silenced U266 compared with Scr cells (2−ΔΔCt formula);  Jagged1, Jagged2 and HES6 were analyzed as control of pathway inhibition 
and 18s and HPRT1 as control of treatment specificity; (E) 48 and 96h post-silencing ELISA assay for RANKL secreted in the CM of  J1/
J2-silenced and Scr U266 cells. Statistical analysis was performed using Two-tailed t-test: *=p<0.05 **=p <0.01. SD were calculated from 
3 independent experiments. 
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Figure 7: Stromal cells stimulate RANKL expression in MM cells in a Notch-dependent manner. Interaction with stromal 
cells promotes osteoclastogenic potential of low-osteoclastogenic OPM2 cells by inducing RANKL secretion. J1/J2 silencing of OPM2 
cells hampers stromal cells effect. (A) OCL formation by Raw264.7 cells cultured with CM from OPM2 cells, CM from NIH3T3 cells, 
or CM from OPM2 cells transfected with J1/J2- or Scr-siRNAs and co-cultured with NIH3T3. TRAP staining and mean value of counted 
OCLs ± SD are shown. Statistical analysis was performed using the ANOVA and Tukey test: *=p<0.05, **= p <0.01. (B) qRT-PCR for 
of RANKL and HES6 genes expression in J1/J2- or Scr-transfected OPM2 co-cultured with NIH3T3 cells compared to Scr-transfected 
OPM2 alone (=1), calculated by the 2−ΔΔCt formula. HES6 as control of pathway activity. Mean values ± SD are shown. Statistical analysis 
by two-tailed t-test :**= p<0.01; ***=p<0.001. (C) ELISA assay on RANKL secreted by OPM2 cell line transfected with J1/J2 or  Scr 
siRNAs and cultured alone or with NIH3T3 cells. Mean values ± SD are shown. Statistical analysis by one way ANOVA and Tukey post 
test: **= p<0.01. (D) Histograms display the levels of intracellular RANKL analyzed by flow cytometry in Scr-transfected OPM-2 in single 
culture (blue line) or in co-culture with HS5 cells (red line) and J1/J2-transfected cells co-cultured HS5 cells (green line); isotype-matched 
control (gray line). (E)  To verify if MM cell-derived Jagged ligand directly contributes to OCL formation by interacting with pre-OCLs, 
Raw264.7 cells were induced to differentiate with 30ng/ml of mRANKL in the presence or absence of 0,5 ng/ml of soluble or immobilized 
Jagged. Graph shows the percentage of multinucleated cells in every culture normalized to mRANKL only treated cells (=100%). Error 
bars represent SD calculated out of 3 independent experiments. Statistical analysis was performed by ANOVA and Tukey test: **= p <0.01; 
***= p <0.001 
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of a co-culture system including NIH3T3 fibroblasts 
as mimic for BM stromal cells. Interestingly, we found 
that CM obtained by co-culturing OPM2 with NIH3T3 
cells had a greater pro-osteoclastogenic potential when 
compared to CM from OPM2 or NIH3T3 cells alone, 
while this effect was absent when J1/J2-silenced OPM2 
cells were co-cultured with NIH3T3 cells (Fig. 7A). 
Accordingly, OPM2 co-cultured with NIH3T3 cells 
displayed increased RANKL and HES6 gene expression 
(Fig. 7B) and secreted RANKL (Fig.7C). These effects 
were dramatically reduced upon J1/J2 silencing (Fig. 7B 
and C). To exclude any possible bias due to the use of a 
murine fibroblast cell line as mimic of BMSCs, the above 
results were confirmed by co-culturing MM cells with 
the human BMSC line HS5. Indeed, Fig. 7D shows that 
HS5 cells increased up to twofold RANKL expression in 
OPM2 cells. This effect was almost completely impaired 
by J1/J2 silencing. These results suggest a new mechanism 
by which BMSCs support MM-associated bone disease 
and indicated its dependency on the expression of Jagged 
ligands on MM cells. 
Although the evidence that CM from MM cells is 
sufficient to drive osteoclastogenesis by  upregulating 
Notch signaling in OCL progenitors, evidences from BM 
metastatic breast cancer cells showed that tumor-derived 
Jagged1 promoted OCLs differentiation by triggering 
Notch activation through a direct contact [34]. Therefore, 
we explored if also MM cells exploited Jagged ligands 
to directly activate Notch signaling in OCL precursors. 
To exclusively assess the level of Notch activation in 
pre-OCLs triggered by Jagged, we induced Raw264.7 
differentiation (30 ng/mL RANKL) in the presence or the 
absence of  Jagged1. We observed that stimulation with 
0.5 μg/ml soluble or immobilized Jagged1 increased OCL 
differentiation (Fig. 7E) when cells were cultured in the 
presence of RANKL, while Jagged1 alone did not affect 
differentiation (data not shown). These findings indicate 
that the autonomous release of RANKL by tumor cells is 
fundamental for MM-induced osteoclastogenesis, and MM 
cell-derived Jagged can further boost OCL differentiation 
by directly triggering the osteoclastogenic Notch signaling 
in OCL precursors.
DISCUSSION
MM is characterized by osteoporosis and bone 
lesions in almost 80% of patients [3]. Osteolysis not only 
affects patients quality of life, but also promotes tumor 
burden [10], angiogenesis [12], drug resistance [35, 36] 
and reduces the patient’s anti-tumor immune response 
[3, 11], thereby contributing to the fatal outcome of MM. 
Therefore bone disease is a relevant issue in MM. 
Notch has been proposed as a promising therapeutic 
target in MM [4, 26, 37]. Notch receptors and ligands 
are dysregulated in MM and positively correlate with 
clinical stage [21-25]. Notch signaling promotes MM cell 
Figure 8: Illustration of the role of Notch ligands and receptors in MM-associated osteoclastogenis. In MM cells Notch 
signaling can be activated in trans (1) by homotypic interaction between neighboring tumor cells or in cis through binding of ligands 
and receptors expressed by the same cell. Notch activation in MM cell results in (3) the autonomous production of the osteoclastogenic 
factor RANKL and the engagement of RANK on osteoclast progenitor (4). In turn, RANK signaling stimulates Notch2 gene expression 
(5) and its transcriptional activity (6). Jagged ligands on myeloma cell surface may contribute to enhance the osteoclastogenic process by 
Notch2 engagement and activation (7). The osteoclastogenic effect of Notch2 signaling results, at least in part, from the increased level of 
RANK (8) and secretion of RANKL (9). Stromal cells can enhance the osteoclastogenic potential of myeloma cells by stimulating their 
autonomous production of RANKL (10). This effect depends on Jagged ligands expressed by myeloma cells.
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proliferation, survival [4, 16, 37-40] and drug resistance 
[38, 41]. Recently, we have described that Notch signaling 
is involved in malignant PC localization at the BM by 
controlling the expression of the chemokine receptor 
CXCR4 [4]. A well-known effect of MM localization in the 
BM is the unbalance of the OCL/OBL ratio by increasing 
osteoclastogenesis and reducing OBL differentiation, 
finally resulting in bone disease. Interestingly, the Notch 
pathway is also determinant in skeletal development and 
remodeling [27, 28]. 
Based on these considerations, we investigated the 
role of Notch signaling in MM-induced osteoclastogenesis 
by: 1) confirming its outcome on OCL differentiation and 
2) analyzing if Notch signaling dysregulation affects the 
osteoclastogenic potential of MM cells.
We confirmed that osteoclastogenesis needs an 
active Notch signaling by inhibiting Notch via DAPT on 
OCL precursors, the murine Raw264.7 monocyte cell line, 
or human monocytes from healthy donors. Interestingly, 
also MM-associated osteoclastogenesis required an active 
Notch signaling. Indeed, getting advantage of co-culture 
systems of MM cells and OCL progenitors (involving 
cell lines as well as primary cells), we observed that  the 
inhibition of Notch signaling hinders the ability of MM 
cells to drive OCL differentiation. These findings raised 
the question if the observed anti-osteoclastogenic effect 
was simply due to Notch inhibition in OCLs or it could be 
also attributed to a reduced Notch signaling in MM cells.
We wondered which could be the contribution of 
Notch signaling to MM cell osteoclastogenic potential 
and reasoned that the contemporaneous expression of 
Notch receptors and ligands could allow MM cells to 
autonomously activate Notch signaling as well as to 
trigger (via surface Jagged) the osteoclastogenic activity of 
Notch on neighboring pre-OCLs (as illustrated in Fig.8). 
Concerning the first point, by using co-culture 
systems, we investigated if the endogenous Notch 
activation resulted in MM cell release of soluble 
osteoclastogenic factors. We demonstrated, for the 
first time, that the osteoclastogenic potential of MM 
cells depended on Notch signaling ability to induce the 
autonomous RANKL secretion (illustrated in Fig.8). Notch 
ability to drive MM cells pro-osteoclastogenic potential is 
mainly due to its capability to regulate RANKL secretion, 
since RANKL neutralization in Raw264.7 cells cultured 
with U266 or U266-CM impaired OCL formation. 
Although our findings indicated that Notch 
activity can promote the osteoclastogenic potential of 
MM cells inducing the secretion of RANKL, not all 
primary MM cells or cell lines produce RANKL and are 
osteoclastogenic. Interestingly, we found that BMSCs 
were able to promote the osteoclastogenic potential of 
MM cells lacking osteoclastogenic properties. Indeed, 
low-osteoclastogenic OPM2 cells co-cultured with 
murine fibroblasts or human BMSCs strongly increased 
RANKL secretion and improved their ability to induce 
OCL formation. Remarkably, this effect required an active 
Notch signaling, since BMSCs could not enhance the 
osteoclastogenic potential of J1/J2-silenced OPM2 cells.  
These findings provide further insight in the 
interaction between MM and BM microenvironment, 
suggesting that Notch signaling deregulation might 
be a key step in MM progression, which provides 
osteoclastogenic potential to MM cells by increasing their 
sensibility to stromal cells stimulation.
The evidence that the osteoclastogenic potential 
of MM cell depends on Notch activity, via the release of 
RANKL, represents an important change in the current 
view. The clinical relevance of these findings stems from 
the following evidences: 1) Notch activity (assessed as 
HES6 gene expression) and RANKL expression are directly 
correlated in primary MM cells and in the differently 
osteoclastogenic MM cells lines (U266 and OPM2) 
used in this work; 2) the inhibition of Notch signaling 
hampers the pro-osteoclastogenic potential of primary 
MM cells; 3) RANKL expression in MM cells correlates 
with osteolytic bone disease [42, 43], and, accordingly, 4) 
RANKL targeting has been reported to prevent myeloma 
bone disease [44]. 
Our investigation on MM cells osteoclastogenic 
properties took in consideration also the effect of the 
direct contact of MM cells with OCL progenitors. We 
reasoned that dysregulated  Jagged ligands expressed on 
MM cell surface [21-25] could engage Notch receptors on 
neighboring pre-OCLs, resulting in the direct activation 
of the osteoclastogenic Notch signaling. To assess if this 
direct interaction occurred, Raw264.7 cells were cultured 
with Jagged1. The evidence that Jagged-stimulated 
Raw264.7 cells doubled RANKL-induced OCL formation 
prompted us to conclude that MM exploits tumor-
derived Jagged to engage Notch receptor in OCLs thus 
increasing RANKL osteoclastogenic effect. Therefore, 
BM-localized tumor cells may take advantage of Jagged 
ligands to promote OCL differentiation in two different 
ways: 1) by directly activating the osteoclastogenic 
Notch pathway in OCL progenitors and 2) inducing 
tumor cells to secrete RANKL autonomously or in 
response to BMSCs stimulation. Of note, while MM-
osteoclastogenic potential is mainly based on RANKL 
secretion, Kang’s group reported that BM metastatic 
breast cancer cells induce osteoclastogenesis exclusively 
by directly activating Notch signaling on OCLs through 
tumor cell-derived Jagged [34]. Therefore the mechanism 
here described is unique. Nonetheless, the exploitation of 
the RANKL-based mechanism by MM cells should not 
surprise. Indeed, the engagement of RANK by RANKL in 
pre-OCL was previously reported as key for physiological 
OCL differentiation, since it resulted in NF-κB and Notch 
activation and the subsequent increase in the expression of 
NFAT1c, a master regulator of osteoclastogenesis [28, 45]. 
We further investigated the molecular events 
triggered by RANKL in OCL progenitors during 
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differentiation (illustrated in figure 8).  One issue regarded 
the controversy on the specific role of the Notch isoforms 
in the osteoclastogenic process. Choi and colleagues [46] 
suggested that RANKL-induced OCL differentiation is 
promoted by Notch1 intracellular domain, whereas Bai et 
al. described Notch1 negative effect on osteoclastogenesis 
[27]. Our data support the concepts that Notch1 activity 
is neither necessary, since it was downregulated during 
RANKL-induced Raw264.7 cells differentiation, nor 
sufficient to induce osteoclastogenesis, due to the observed 
lack of differentiation of ICN1-transfected Raw264.7 
cells. Oppositely, the RANKL-dependent increase of 
Notch2 during Raw264.7 cells differentiation confirmed 
that this isoform is essential as previously reported by 
Fukushima et al. [28]. Nonetheless, differently from 
these authors, who reported that Notch2 boosted OCL 
differentiation induced by RANKL, our results indicated 
that Notch2 forced expression alone was sufficient to 
stimulate osteoclastogenesis by promoting an autonomous 
secretion of RANKL in Raw264.7 cells. 
The other relevant information generated by this 
work concerns a new form of cooperation of Notch 
with the NF-kB pathway during OCL differentiation. 
The evidences that RANK increase during Raw264.7 
cell differentiation can be hampered by Notch inhibition 
indicates that Notch signaling activation, observed 
during osteoclastogenesis, increases pre-osteoclast 
responsiveness to RANKL by promoting the expression 
of its receptor RANK. 
The relevance of the two dysregulated Jagged 
ligands in the MM cell osteoclastogenic ability, makes 
them promising targets for a Notch inhibitory approach 
aiming to counteract the MM-related osteoclastogenesis 
and co-morbidities. Indeed, we observed that Jagged1 and 
Jagged2 silencing in U266 cells decreased Notch activity 
along with the ability to induce OCL differentiation via a 
direct or indirect (RANKL-mediated) activation of Notch 
activity on Raw264.7 cells. Moreover, we demonstrated 
that even the expression of RANKL induced by interaction 
with stromal cells in naturally low RANKL-expressing 
cells, such as OPM2, could be inhibited by J1/J2 silencing. 
Moreover J1/J2 silencing can effectively inhibit the 
autonomously activated Notch signaling, whose promoting 
effects on MM growth and survival have been widely 
illustrated in the recent years [3, 4, 23, 24, 26, 38, 41]. 
A Notch-directed approach based on Jagged 
inhibition could be  more selective and safe if compared 
with GSIs which causes gut toxicity due to the 
contemporaneous inhibition of all the Notch isoforms 
[3]. The redundancy of Notch ligands and the efficacy of 
Jagged1 and Jagged2 inhibition in reducing the excessive 
Notch signaling in MM cells, may provide the rational 
for an effective and safer Notch-directed approach to 
target MM patients bone disease and the associated co-
morbidities, including increase in tumor burden [10], 
angiogenesis [12], drug resistance [35, 36] and inhibition 
of immune response [3, 11]. 
MATERIALS AND METHODS
Cells and treatments
All cells were maintained in 5% CO2 atmosphere. 
The murine cell lines Raw264.7 and NIH3T3 and the 
human BMSC line HS5 were cultured in complete DMEM 
medium with 10% heat inactivated FBS, the human MM 
cell lines U266 and OPM2 in complete RPMI1640 with 
10% heat inactivated FBS. Following reconstitution 
in DMSO, DAPT (Sigma Aldrich, Germany) was 
administered to cells at a final concentration of 50μM. 
Recombinant mouse RANKL (mRANKL, Peprotech, 
USA) was used at the final concentration of 50ng/ml. Anti-
RANKL neutralizing antibody (Peprotech, USA) was used 
at the final concentration of 0.10μg/ml.
Osteoclastogenesis assays
OCL differentiation was induced as reported in each 
experiment. On the day of harvest, cells were fixed on the 
culture plates with citrate-acetone solution and stained for 
TRAP (Sigma-Aldrich). Osteoclasts were identified and 
enumerated under light microscopy as TRAP+ cells with 
≥3 nuclei. Further details on treatments and experimental 
procedures are provided in Supplemental Information.
Bone resorption assay 
Raw264.7 were cultured on Osteo Assay Surface 
24-wells plates (Corning) under differentiation conditions. 
After 7-10 days of culture, the plates were washed in 
5% sodium hypochlorite solution to remove the cells. 
The resorbed areas on the plates were captured with 
EVOS fl microscope and measured by using the Wimasis 
image analysis software (GmbH) to process 20x pictures 
covering the whole well surface.
qRT-PCR
Total RNA from cell lines was isolated, cDNA was 
prepared and Quantitative PCR (qPCR) was performed as 
previously described [4]. Total mRNA for qRT-PCR on 
primary human cells was isolated using the miRNeasy kit 




Flat-bottom 96-well polycarbonate plates were 
coated at 4°C overnight with 50 µL/well cell culture 
supernatants diluted 1:1 in carbonate coating buffer (0.1 
M Na2CO3, 0.1 M NaHCO3, pH=9.5). Standard curves 
were obtained with serial dilutions of purified recombinant 
human RANKL (Merck-Millipore) or recombinant 
mouse RANKL (Peprotech). After blocking with PBS 
supplemented with 1% W/V BSA, plates were incubated 
with biotin-conjugated goat anti-human RANKL (Merck-
Millipore) or rabbit anti-mouse RANKL (Peprotech, USA) 
for 1 h at RT. Then, plates were washed with PBS- 0.025% 
V/V Tween-20 and incubated at RT with Streptavidin-
HRP-labeled secondary antibody (Invitrogen) or with 
a mouse anti-rabbit secondary antibody (Santa Cruz 
Biotechnology, Inc) for 30 min. The plates were washed, 
then the TMB substrate (Thermo Scientific, Inc) was 
added, and signal was measured using a microplate reader. 
All samples were run in triplicates.
RNAi Assay
Two stealth small interference RNA 





ACAGAUGCCACCAUUGUAGCAAGGC) and a 
negative control were purchased from Invitrogen. Select 
RNAiTM siRNA system (Invitrogen) was used according 
to the manufacturer’s guidelines. 
Transfections 
Intracellular Notch1 (ICN1) and Notch2 (ICN2) 
constructs were as described (47, 48). One hundred 
microliters of Raw264.7 cell suspension (107/mL) in 
RPMI1640 w/o antibiotics were mixed with 5 μg DNA, 
transferred into a 2.0 mm-gap cuvette (BTX, MA, USA), 
electroporated at 250 V and 950 μF and cultured for 3 days 
in a 6-well plate.  
Gene expression profiling
BM highly purified (CD138 ≥ 90%) PC samples 
from 55 newly diagnosed MM patients were profiled on 
the GeneChip Human Gene 1.0 ST array (Affymetrix, 
Santa Clara, CA). Gene expression profiling data were 
generated as previously described [31]. The Institutional 
Review Board of Fondazione IRCCS Policlinico Ca’ 
Granda, Milano, Italy, approved the design of this 
study. Written informed consent in accordance with the 
Declaration of Helsinki was obtained.
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